A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines

Cancer Lett. 2003 Mar 20;192(1):67-74. doi: 10.1016/s0304-3835(02)00690-0.

Abstract

ErbB4 (HER4) is a member of the ErbB family of receptor tyrosine kinases, a family that also includes the Epidermal Growth Factor Receptor (EGFR/ErbB1/HER1), Neu/ErbB2/HER2, and ErbB3/HER3. Several groups have hypothesized that signal transduction by the ErbB4 receptor tyrosine kinase is coupled to differentiation, growth arrest, and tumor suppression in mammary and prostate epithelial cells. In this report we demonstrate that a constitutively active ErbB4 mutant inhibits the formation of drug-resistant colonies by the DU-145 and PC-3 human prostate tumor cell lines. This is consistent with our hypothesis that ErbB4 signaling is growth inhibitory and may be coupled to tumor suppression in prostate cells.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Cell Division
  • Drug Resistance, Neoplasm*
  • ErbB Receptors / genetics*
  • ErbB Receptors / metabolism*
  • Fibroblasts
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Male
  • Mice
  • Mutation / genetics*
  • Phosphorylation
  • Phosphotyrosine / metabolism
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / pathology*
  • Receptor, ErbB-4
  • Tumor Cells, Cultured

Substances

  • Phosphotyrosine
  • ERBB4 protein, human
  • ErbB Receptors
  • Erbb4 protein, mouse
  • Receptor, ErbB-4